Real-world Effectiveness of Antipsychotics for the Treatment of Negative Symptoms in Patients with Schizophrenia with Predominantly Negative Symptoms

Abstract

Introduction

This study assessed the comparative effectiveness of antipsychotics in the treatment of patients with schizophrenia presenting with prominent negative symptoms and no-to-mild positive symptoms.

Methods

Data were taken from a 3-year prospective, international, observational study (n=17 384). This post-hoc study focused on 3 712 patients who started antipsychotic monotherapy and had moderate-to-severe negative symptoms and no-to-mild positive symptoms (Clinical Global Impression-Severity Scale [GGI-SCH]). Patients were classified into 3 treatment cohorts: olanzapine, other atypicals and typicals. Multiple regression analyses were performed.

Results

All treatment groups experienced improvement in negative symptoms and social functioning during follow-up. The adjusted mean change in the CGI-SCH negative symptoms scores during follow-up was greater for olanzapine-treated patients by 0.220 (p<0.001) (vs. other atypicals) and by 0.453 (p<0.001) (vs. typicals). Olanzapine-treated patients were also most likely to achieve response of negative symptoms and improvement in social functioning, and to stay on the initial medication longer.

Discussion

Patients with schizophrenia treated with antipsychotics experienced improvement in negative symptoms and social functioning during follow-up. Olanzapine appeared to be more effective compared with other antipsychotics.

Key words

antipsychotics - negative symptoms - schizophrenia - SOHO

• References

• 1 Mueser KT, McGurk SR. Schizophrenia. Lancet 2004; 363: 2063-2072
• 2 Velligan DI, Mahurin RK, Diamond PL. et al. The functional significance of symptomatology and cognitive function in schizophrenia. Schizophr Res 1997; 25: 21-31
• 3 Lysaker PH, Davis LW. Social function in schizophrenia and schizoaffective disorder: associations with personality, symptoms and neurocognition. Health Quality Life Outcomes 2004; 2: 15
• 4 Lysaker PH, Lancaster RS, Nees MA. et al. Attributional style and symptoms as predictors of social function in schizophrenia. J Rehabil Res Dev 2004; 41: 225-232
• 5 Norman RM, Malla AK, McLean T. et al. The relationship of symptoms and level of functioning in schizophrenia to general wellbeing and the Quality of Life Scale. Acta Psychiatr Scand 2000; 102: 303-309
• 6 Milev P, Ho BC, Arndt S. et al. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry 2005; 162: 495-506
• 7 Kirkpatrick B, Fischer B. Subdomains within the negative symptoms of schizophrenia: commentary. Schizophr Bull 2006; 32: 246-249
• 8 Ho BC, Nopoulos P, Flaum M. et al. Two-year outcome in first-episode schizophrenia: predictive value of symptoms for quality of life. Am J Psychiatry 1998; 155: 1196-1201
• 9 Rocca P, Montemagni C, Castagna F. et al. Relative contribution of antipsychotics, negative symptoms and executive functions to social functioning in stable schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 373-379
• 10 Rabinowitz J, Levine SZ. Garibaldi G et al. Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data. Schizophr Res 2012; 137: 147-150
• 11 Carpenter Jr WT, Heinrichs DW, Wagman AM. Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 1988; 145: 578-583
• 12 Moller HJ. Neuroleptic treatment of negative symptoms in schizophrenic patients. Efficacy problems and methodological difficulties. Eur Neuropsychopharmacol 1993; 3: 1-11
• 13 Jibson MD, Tandon R. New atypical antipsychotic medications. J Psychiatr Res 1998; 32: 215-228
• 14 King DJ. Drug treatment of the negative symptoms of schizophrenia. Eur Neuropsychopharmacol 1998; 8: 33-42
• 15 Moller HJ. Atypical neuroleptics: a new approach in the treatment of negative symptoms. Eur Arch Psychiatry Clin Neurosci 1999; 249 (Suppl. 04) 99-107
• 16 Darba J, Minoves A, Rojo E. et al. Efficacy of second-generation antipsychotics in the treatment of negative symptoms of schizophrenia: a meta-analysis of randomized clinical trials. Rev Psiquiatr Salud Ment 2011; 4: 126-143
• 17 Leucht S, Corves C, Arbter D. et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373: 31-41
• 18 Lecrubier Y, Perry R, Milligan G. et al. Physician observations and perceptions of positive and negative symptoms of schizophrenia: a multinational, cross-sectional survey. Eur Psychiatry 2007; 22: 371-379
• 19 Haro JM, Edgell ET, Jones PB. et al. The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment. Acta Psychiatr Scand 2003; 107: 222-232
• 20 Haro JM, Edgell ET, Novick D. et al. Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study. Acta Psychiatr Scand 2005; 111: 220-231
• 21 Dossenbach M, Arango-Davila C, Silva Ibarra H. et al. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. J Clin Psychiatry 2005; 66: 1021-1030
• 22 Karagianis J, Novick D, Pecenak J. et al. Worldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO): baseline characteristics of pan-regional observational data from more than 17,000 patients. Int J Clin Pract 2009; 63: 1578-1588
• 23 APA. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition Washington, DC: American Psychiatric Association (APA); 1994
• 24 WHO. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva, Switzerland: World Health Organisation (WHO); 1992
• 25 Haro JM, Kamath SA, Ochoa S. et al. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl 2003; [pii]: 16–23
• 26 Cohen J. Statistical power analysis for the behavioral sciences. 2^nd ed. Hillsdale, NJ: Lawrence Eribaum Associates; 1988
• 27 Kirkpatrick B, Fenton WS, Carpenter Jr WT. et al. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 2006; 32: 214-219
• 28 Moller HJ, Muller H, Borison RL. et al. A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study. Eur Arch Psychiatry Clin Neurosci 1995; 245: 45-49
• 29 Tandon R. Quetiapine has a direct effect on the negative symptoms of schizophrenia. Hum Psychopharmacol 2004; 19: 559-563
• 30 Turkoz I, Bossie CA, Dirks B. et al. Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia. Neuropsychiatr Dis Treat 2008; 4: 949-958
• 31 Tollefson GD, Sanger TM. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 1997; 154: 466-474
• 32 Haro JM, Novick D, Suarez D. et al. Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study. J Clin Psychopharmacol 2006; 26: 571-578
• 33 Haro JM, Suarez D, Novick D. et al. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol 2007; 17: 235-244
• 34 Lieberman JA, Stroup TS, McEvoy JP. et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223
• 35 Swartz MS, Perkins DO, Stroup TS. et al. Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. Schizophr Bull 2003; 29: 33-43